Carola Riva
6PUBLICATIONS
45CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Feb 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.Raffaele Palmieri, Fabio Guolo, Luana Fianchi
|Feb 11, 2026
Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.Salvatore Perrone, Andrea Corbingi, Calogero Vetro
|Dec 05, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.Raffaele Palmieri, Fabio Guolo, Luana Fianchi
|Sep 24, 2025
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.Fabio Guolo, Luana Fianchi, Maria Paola Martelli
|Jan 20, 2025
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.Giovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone
|Dec 05, 2024
Comparing Outcomes Between CPX-351 and Fludarabine-Based Induction in Secondary Acute Myeloid Leukemia in the Real-World Setting: The Prognostic Role of Measurable Residual Disease.Carola Riva, Paola Minetto, Maria Chies
Pageof 1
Frequent Collaborators
5 joint publications
Calogero Vetro
5 joint publications
Fabio Guolo
4 joint publications
Maria Paola Martelli
4 joint publications
Salvatore Perrone
4 joint publications
Daniela Cilloni
4 joint publications
Paola Minetto
3 joint publications
Marco Cerrano
3 joint publications
Massimo Breccia
3 joint publications
Alessandro Isidori
3 joint publications
Patrizia Chiusolo
